Abstract
We evaluated the association of longitudinal changes in circulating levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) and high sensitivity cardiac troponin T (hs-cTnT) with the burden of arrhythmias as captured by 2-week ambulatory ECG monitoring. This study included 1,930 Atherosclerosis Risk in Communities Study participants who wore a leadless, ambulatory ECG monitor (Zio XT Patch) at visit 6 (2016 to 2017) and had cardiac biomarkers measured at visit 6 and visit 4 (median of 19 years earlier). The mean age of participants at V6 was 79 ± 5 years, 41% were men, and 22% were black. Adjusting for demographics, body mass index, smoking, diabetes, hypertension, stroke, left ventricular mass, cardiac medications, patch wear time, visit 4 levels of NT-proBNP and hs-cTnT, and relative change in hs-cTnT, each log-transformed unit relative increase in NT-proBNP was associated with a higher likelihood of nonsustained ventricular tachycardia (odds ratio 1.29, 95% confidence interval [CI] 1.12 to 1.48), a higher number of daily atrial tachycardia episodes (geometric mean ratio [GMR] 1.16, 95% CI 1.10 to 1.21), and a higher daily ectopic burden (premature ventricular contractions —GMR 1.42, 95% CI 1.25 to 1.62; premature atrial contractions —GMR 1.40, 95% CI 1.25 to 1.57). In fully adjusted analyses, each log-transformed unit relative increase in hs-cTnT was only found to be weakly associated with a higher daily premature ventricular contraction burden (GMR 1.31, 95% CI 1.01 to 1.70). In conclusion, longitudinal change in NT-proBNP was associated with an increased atrial and ventricular arrhythmia burden.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 45-52 |
| Number of pages | 8 |
| Journal | American Journal of Cardiology |
| Volume | 158 |
| DOIs | |
| State | Published - Nov 1 2021 |
Bibliographical note
Funding Information:Funding sources: The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700005I, HHSN268201700004I). This work was also supported by grants from the National Heart Lung and Blood Institute (R01HL126637 [Dr Chen], R01HL141288 [Dr Chen], K24HL155813 [Dr. Chen], R01HL134320 [Dr Ballantyne and Selvin], K24HL148521 [Dr Alonso], K24HL152440 [Dr Selvin]), the National Institute of Diabetes, Digestive and Kidney Diseases (R01 DK089174 [Dr Selvin]), the National Institute of General Medical Sciences (T32GM132063 [Dr Wang]), and the American Heart Association (16EIA26410001 [Dr Alonso]), Dallas, TX.
Publisher Copyright:
© 2021 Elsevier Inc.
